1,1'-Carbonyldiimidazole → tert-butyl [(3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)methyl]carbamate
反応式
[CH3:1][NH:2][C:3]1[CH:4]=[C:5]([CH2:12][NH:13][C:14](=[O:20])[O:15][C:16]([CH3:19])([CH3:18])[CH3:17])[CH:6]=[CH:7][C:8]=1[N+:9]([O-])=O.[H][H].C1N=CN([C:28](N2C=NC=C2)=[O:29])C=1>C1COCC1.[Pd]>[CH3:1][N:2]1[C:3]2[CH:4]=[C:5]([CH2:12][NH:13][C:14](=[O:20])[O:15][C:16]([CH3:19])([CH3:18])[CH3:17])[CH:6]=[CH:7][C:8]=2[NH:9][C:28]1=[O:29]参加物
実験手順
To a suspension of tert-butyl [(3-methylamino-4-nitrophenyl)methyl]carbamate (864 mg, 3.07 mmol) and 10% Pd—C (100 mg) in THF was charged with hydrogen carefully. After stirring for 6 hours at room temperature, the reaction was recharged with nitrogen. Then, filtration, evaporation gave the residue, which was used for further reaction without purification. To the THF solution of the above, CDI (597 mg, 3.68 mmol) was added and the mixture was stirred for 4 hours at room temperature. After evaporation, purification through silica gel column chromatography eluting with CH2Cl2/MeOH (15:1) gave tert-butyl [(3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)methyl]carbamate as white solid (658 mg, 77%). 1H NMR (CDCl3): δ 1.47 (9H, s), 4.35 (2H, d, J=5.2 Hz), 4.92 (2H, brs), 6.86-7.10 (3H, m), 9.73 (1H, brs) MS (ESI) m/z 278 (M+H)+.
後処理
- filtrationThen, filtration, evaporation
- customgave the residue, which
- customwas used for further reaction without purification
- stirringthe mixture was stirred for 4 hours at room temperature
- customAfter evaporation, purification through silica gel column chromatography
- washeluting with CH2Cl2/MeOH (15:1)
出典と根拠
- ORDレコード
- ord-510fa389d8134ca0941a71e82adbc96e
- 出典データセット
- uspto-grants-2009_04
- 特許番号
- US07514457B2
反応ノート
読み込み中…